Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 29Cisplatin 19Carboplatin 13Cetuximab 12Radiotherapy 10Paclitaxel 9Surveys and Questionnaires 8Docetaxel 6Radiotherapy, Intensity-Modulated 5Surgical Procedures, Operative 4Standard of Care 4130-nm albumin-bound paclitaxel 4dostarlimab 3Therapeutics 3Nivolumab 3Fluorouracil 3Cyclophosphamide 3Chemoradiotherapy 3Blood Specimen Collection 3Albumin-Bound Paclitaxel 3toripalimab 2nimotuzumab 2fludarabine 2durvalumab 2atezolizumab 2abemaciclib 2X-Rays 2Taxes 2Radiosurgery 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × patritumab deruxtecan × 90 days × Clear all
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡